GSK and Oxford University Partner on £50M Cancer Vaccine Research

The collaboration aims to develop vaccines targeting pre-cancerous cells, potentially preventing cancer decades before it develops.

GSK will invest £50 million over three years in a research partnership with the University of Oxford focused on cancer prevention through vaccines.
The program targets pre-cancerous cells, aiming to stop cancer before it fully develops, leveraging Oxford's expertise in pre-cancer biology and neoantigen research.
Scientists highlight that many cancers take up to 20 years to develop, making early intervention at the pre-cancer stage a groundbreaking approach.
The research builds on advancements in immunology and mRNA technology, which have enabled the detection of early cancer markers and the design of targeted vaccines.
The initiative reflects growing optimism about cancer vaccines and is supported by the UK government as a step forward in transforming cancer prevention and treatment.